



Press Release

Dr Graham Kelly Discusses Novogen's Cantrixil Program

SYDNEY (December 5, 2014) - Novogen Ltd (ASX:NRT, NASDAQ:NVGN)

Novogen Ltd releases its latest video presentation. In this presentation, Dr Kelly discusses Novogen lead drug candidate Cantrixil and the clinical trial due to start in mid-2015. Cantrixil is a first-in-class chemotherapy developed specifically to be injected into the body's two main cavities – the peritoneal cavity and the pleural cavity. Cantrixil is a world-first development in being able to kill the full range of cells within a tumor, but particularly the cancer stem cells, across all forms of cancer known to arise in the abdomen.

Please follow the link <http://youtu.be/0zZoTLIZx2M>

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on the Company's website, www.novogen.com

For more information please contact:

Corporate Contact

Executive Chairman & CEO
Novogen Group

Media Enquiries

Operations Manager
Novogen Group



Graham.Kelly@novogen.com
+61 (0) 2 9472 4100

Cristyn.Humphreys@novogen.com
+61 (0) 2 9472 4111

